Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vibeke Strand

Showing results (201-210 of 435) with videos related to

Pageof 44
Sort By:
Annals of the Rheumatic Diseases|March 11, 2016
The changing landscape of biosimilars in rheumatologyThomas Dörner, Vibeke Strand, Paul Cornes, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 15, 2017
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic ReviewVibeke Strand, Alejandro Balsa, Jamal Al-Saleh, et al.
The Journal of Rheumatology. Supplement|June 2, 2004
Lefunomide in combination therapyJoachim R Kalden, Josef S Smolen, Paul Emery, et al.
The Journal of Rheumatology. Supplement|June 2, 2004
The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapyJosef S Smolen, Paul Emery, Joachim R Kalden, et al.
Current Medical Research and Opinion|May 26, 2021
Immune-mediated diseases and thromboembolic events: a modified Delphi panelNassir Azimi, Freddy Caldera, Stan Cohen, et al.
The Journal of Rheumatology|January 14, 2004
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst, Michael H Schiff, Roy M Fleischmann, et al.
The Lancet. Rheumatology|May 5, 2025
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trialVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
Rheumatology and Therapy|November 10, 2023
Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid ArthritisJeffrey R Curtis, Vibeke Strand, Steven J Golombek, et al.
The Journal of Rheumatology. Supplement|June 2, 2004
Leflunomide: a manageable safety profilePeit L C M van Riel, Josef S Smolen, Paul Emery, et al.
The Lancet. Rheumatology|July 23, 2025
Reassessing antimalarial use in long-term SLE clinical trials - Authors' replyVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
Pageof 44

Showing results (201-210 of 435) with videos related to

Sort By:
Pageof 44
Annals of the Rheumatic Diseases|March 11, 2016
The changing landscape of biosimilars in rheumatologyThomas Dörner, Vibeke Strand, Paul Cornes, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 15, 2017
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic ReviewVibeke Strand, Alejandro Balsa, Jamal Al-Saleh, et al.
The Journal of Rheumatology. Supplement|June 2, 2004
Lefunomide in combination therapyJoachim R Kalden, Josef S Smolen, Paul Emery, et al.
The Journal of Rheumatology. Supplement|June 2, 2004
The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapyJosef S Smolen, Paul Emery, Joachim R Kalden, et al.
Current Medical Research and Opinion|May 26, 2021
Immune-mediated diseases and thromboembolic events: a modified Delphi panelNassir Azimi, Freddy Caldera, Stan Cohen, et al.
The Journal of Rheumatology|January 14, 2004
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst, Michael H Schiff, Roy M Fleischmann, et al.
The Lancet. Rheumatology|May 5, 2025
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trialVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
Rheumatology and Therapy|November 10, 2023
Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid ArthritisJeffrey R Curtis, Vibeke Strand, Steven J Golombek, et al.
The Journal of Rheumatology. Supplement|June 2, 2004
Leflunomide: a manageable safety profilePeit L C M van Riel, Josef S Smolen, Paul Emery, et al.
The Lancet. Rheumatology|July 23, 2025
Reassessing antimalarial use in long-term SLE clinical trials - Authors' replyVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
Pageof 44